InflaRx Reports Positive Results from the Open Label Extension Part of the SHINE Study for IFX-1 in Hidradenitis Suppurativa

November 7, 2019 2:10 AM

70.6% of week 16 HiSCR responders maintain response throughout week 40 while 41.8% of non-responders become responders (total HiSCR rate = 56.3% at end of treatment) 78.2% of OLE patients complete extension period and show marked reduction in all inflammatory lesions IFX-1 long-term treatment well tolerated, no drug-related serious adverse events Conference call to provide details and corporate strategic update scheduled for 7 November...

Read more

Calmare Therapeutics Has $842,000 Judgment Vacated by the U.S. Court Of Appeals for the Second Circuit

November 6, 2019 10:30 AM

FAIRFIELD, CT / ACCESSWIRE / November 6, 2019 / Calmare Therapeutics Incorporated, (OTC PINK:CTTC) ("CTI"), the pain mitigation company ("Calmare"), has $841,673.85 judgment vacated by the United States Court of Appeals for the Second Circuit (the "Court"). On September 29, 2017, the District Court of Connecticut entered a final judgment awarding GEOMC Co. Ltd. - a South Korea corporation - attorneys' fees in...

Read more

Cofactor Genomics Opens Early Access to New T Cell Exhaustion Models through Predictive Immune Modeling Platform

November 6, 2019 8:01 AM

-- Announces "Functional to FFPE" Early-Access Grant Program -- SAN FRANCISCO, CA / ACCESSWIRE / November 6, 2019 / Cofactor Genomics, leaders in RNA-based technologies and diagnostics, announced today they will provide early access to a new feature in their Predictive Immune Modeling platform which enables cell-state characterization within FFPE tissue samples. Measuring cell-states, such as T cell exhaustion, has been cited as...

Read more

Leading Denver-Based Orthopedic Surgeon to Join Vitro Biopharma's Scientific Advisory Board

November 5, 2019 12:35 PM

GOLDEN, CO / ACCESSWIRE / November 5, 2019 / Vitro Diagnostics, Inc. (OTCPK:VODG), dba Vitro Biopharma announced the appointment of Dr. In Sok Yi MD to its Scientific Advisory Board (SAB). Dr Yi is board certified in Orthopedic Surgery and Surgery of the Hand. He presently practices with Peak Orthopedics and Spine in Englewood Colorado. Dr Yi has a strong background in academic medicine and clinical practice. Following his medical training,...

Read more

Pieris Pharmaceuticals to Present Phase 1 Data for 4-1BB/HER2 Bispecific PRS-343 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

November 5, 2019 8:00 AM

BOSTON, MA / ACCESSWIRE / November 5, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that the Company will present phase 1 dose-escalation monotherapy data for PRS-343, a 4-1BB/HER2 bispecific for the treatment of HER2-positive solid tumors,...

Read more

Edesa Biotech Announces Upcoming Conference Schedule

November 5, 2019 7:30 AM

TORONTO, ON / ACCESSWIRE / November 5, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, announced today that its management will present at the H.C. Wainwright 5th Annual Israel Conference in Tel Aviv, Israel. The company is scheduled to participate in a panel discussion related to initial public offerings and reverse acquisitions on November 10, 2019 at 1:00 pm (IST) at the Hilton Tel Aviv hotel. Edesa...

Read more

Pieris Pharmaceuticals Announces $32 Million Private Placement and Potential Funding Mechanism for PRS-060 Co-development Opt-in

November 4, 2019 8:00 AM

BOSTON, MA / ACCESSWIRE / November 4, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it has entered into a securities purchase agreement with existing and new institutional investors to raise $32 million. The private placement was...

Read more

Pieris Pharmaceuticals to Host Third Quarter 2019 Investor Call and Corporate Update on November 11, 2019

November 4, 2019 7:00 AM

BOSTON, MA / ACCESSWIRE / November 4, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a third quarter 2019 investor call on Monday, November 11, 2019 at 8:00 AM EST to discuss financial results and provide a corporate...

Read more

INTERIM MANAGEMENT STATEMENT - Q3 2019: Encouraging Additional Phase 3 Data Presented for Abicipar, and Start of Phase 1 Trial for MP0310, the First Immuno-oncology DARPin(R) with a Novel Therapeutic Design

October 31, 2019 2:00 AM

Research & Development: MP0310 (FAP x 4-1BB): First patient dosed in phase 1 trial for this tumor-localized immune-modulator, representing a key milestone as the first novel therapeutic design of an immuno-oncology DARPin® candidate in clincial development (in co-development with Amgen) MP0250 (VEGF x HGF) in Multiple Myeloma: Update on ongoing phase 2 PI trial (in combination with Velcade®) to be provided at ASH and...

Read more

Dyadic to Report Third Quarter 2019 Financial Results on Wednesday November 13, 2019

October 30, 2019 4:30 PM

JUPITER, FL / ACCESSWIRE / October 30, 2019 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to help accelerate the development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products at flexible commercial scales, today announced that it will report its financial results...

Read more

Frelii Announces Shareholder Update

October 30, 2019 9:00 AM

LEHI, UT / ACCESSWIRE / October 30, 2019 / Frelii, Inc. (OTC PINK:FRLI) ("Frelii" or "the Company"), a biotechnology company working to commercialize its patent-pending DNA gene sequencing artificial intelligence technology, announced today an update to shareholders regarding technology and marketing advancements. Frelii's CEO, Ian Jenkins stated, "Over the past year, through the diligence of our development team,...

Read more

ReShape Lifesciences Appoints Thomas Stankovich as Chief Financial Officer

October 30, 2019 8:00 AM

SAN CLEMENTE, CA / ACCESSWIRE / October 30, 2019 / ReShape Lifesciences Inc. (OTCQB:RSLS), a leading developer and distributor of minimally invasive medical devices to treat obesity and metabolic diseases, announced today the appointment of Thomas Stankovich as Chief Financial Officer (CFO) effective immediately. "We are happy to have Tom join our senior leadership team as CFO," commented Bart Bandy, President and Chief Executive...

Read more

Xenetic Biosciences, Inc. to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference

October 29, 2019 7:05 AM

FRAMINGHAM, MA / ACCESSWIRE / October 29, 2019 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART, a personalized chimeric antigen receptor T cell ("CAR T") platform technology engineered to target patient-specific tumor neoantigens, announced today that Jeffrey Eisenberg, Chief Executive Officer of Xenetic, will present at the Dawson James...

Read more

Dyadic Announces New Collaboration with Leading Animal Health Company

October 28, 2019 8:00 AM

JUPITER, FL / ACCESSWIRE / October 28, 2019 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global platform biotechnology company, announced today that it has entered into a fully funded collaboration with one of the leading animal health companies to demonstrate the C1 technology for expression and production of therapeutic proteins for companion and farm animal health diseases.Under the terms of the agreement, Dyadic...

Read more

Principal Investigator Dr. Jorge Hernando Ulloa Presents 6 Month VenoValve Data at the 20th Congress of Asian Society for Vascular Surgery

October 24, 2019 4:05 PM

VenoValve Patients Continue to Improve at 6 Months IRVINE, CA / ACCESSWIRE / October 24, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that Dr. Jorge Hernando Ulloa, the Principal Investigator for HJLI's first-in-human VenoValve study in Bogota, Colombia, presents new six (6) month VenoValve data at the 20th Congress of Asian...

Read more

Principal Investigator Dr. Jorge Hernando Ulloa to Present VenoValve Six Month Data at the 20th Congress of Asian Society for Vascular Surgery on October 25, 2019

October 22, 2019 1:00 PM

IRVINE, CA / ACCESSWIRE / October 22, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that on Friday October 25, 2019, Dr. Jorge Hernando Ulloa, the Principal Investigator for HJLI's first-in-man VenoValve® study in Bogota, Colombia, will present six month data on the VenoValve at the 20th Congress of Asian Society for Vascular...

Read more

Cantabio Pharmaceuticals and Luxembourg Institute of Health Collaborate to Research the Therapeutic targeting of the DJ-1 Protein to Treat Immune Associated Diseases

October 21, 2019 12:47 PM

Collaboration aims to explore the use of Cantabio's DJ-1 protein targeting small molecule drug candidates in immune associated diseases at Luxembourg Institute of Health PALO ALTO, CA / ACCESSWIRE / October 21, 2019 / Cantabio Pharmaceuticals, Inc. ("Cantabio" or the "Company"), a preclinical stage pharmaceutical company developing disease modifying therapeutics for Alzheimer's, Parkinson's and related...

Read more

Global Partners LP Raises Over $65,000 for Cure Rare Disease

October 21, 2019 9:05 AM

Fueling groundbreaking development of precision medicine therapeutics to treat Duchenne muscular dystrophy and more. BOSTON, MA, / ACCESSWIRE / October 21, 2019 / Global Partners LP, a third-generation family-founded business, operating one of the largest networks of gas stations and convenience stores in the Northeast, announced today that it raised over $65,000 for Cure Rare Disease (CRD), a Boston-based non-profit organization committed to...

Read more

Edesa Biotech Enrolls First Patient in Phase 2b Dermatitis Study

October 21, 2019 7:30 AM

TORONTO, ON / ACCESSWIRE / October 21, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today announced that the first patient has been enrolled in a Phase 2b clinical trial evaluating the company's lead product candidate, EB01, as a monotherapy for patients with moderate to severe chronic allergic contact dermatitis (ACD). The U.S. Food and Drug Administration recently approved Edesa's clinical...

Read more

Great Bay Bio and Boji Medical have Reached Strategic Cooperation to Jointly Develop a Long-Acting Biological and Innovative Anti-Anemia Injection

October 18, 2019 3:25 AM

HONG KONG, CHINA / ACCESSWIRE / October 18, 2019 / Great Bay Bio, a leading AI biotechnology company dedicated to big data-driven CMC (Chemistry Manufacturing and Controls) development of innovative biologics, is pleased to announce that a strategic cooperation was reached with Guangzhou Boji Medical Biotechnological Co., Ltd. (hereinafter referred to as "Boji Medical ") to jointly develop GBB101, a new long-acting injectable biologics...

Read more